523 results on '"Schetelig, Johannes"'
Search Results
2. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
3. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
4. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
6. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT
7. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
9. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
10. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
11. Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation
12. The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation
13. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
14. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
15. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
16. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
17. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
18. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy
19. Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry
20. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML
21. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
22. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation
23. Potential of TCR sequencing in graft-versus-host disease
24. Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01.
25. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia
26. Klonale Hämatopoese – Bedeutung für die Zelltherapie
27. Handling missing covariate data in clinical studies in haematology
28. Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions
29. Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study
30. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
31. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation
32. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
33. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears
34. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
35. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
36. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
37. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
38. Clonal hematopoiesis and its emerging effects on cellular therapies
39. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
40. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy
41. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS
42. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
43. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
44. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
45. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.
46. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma
47. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
48. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
49. The clinical mutatome of core binding factor leukemia
50. Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.